Dear Members,
Dear Members,
The scientific work within cardiology continues as usual. The journal receives more and more submissions, which is very encouraging for us. However, right now there is a dark cloud over Europe. A brutal war is going on in Europe. We did not expect to experience that a European country attacks another neighbour European country. My sincere hope is that diplomacy can replace brutal war acts.
In this newsletter and in the European Journal of Cardiovascular Pharmacotherapy we would like to focus on new cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer treatment, out-of-hospital cardiac arrest, Fabry disease, beta-blocker use after myocardial infarction in patients with normal ejection fraction, cardio-renal benefits of SGLT2 Inhibitors and interpretation of clinical trials.
Please also see the Pharmapulse section in this issue of the journal, where updates from the American Heart Association Scientific Sessions: cardiovascular pharmacotherapy is noted. Furthermore, sections on Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021 are summarized and questions about: 1) Does the arrival of factor XI inhibitors mark the end of the NOAC era? and 2) Are SGLT2 inhibitors effective against ‘all’ heart failure with preserved ejection fraction? are debated.
In relation to our educational courses detailed information regarding programs are found on our webpage. During 2022 we will also launch several educational and interactive webinars, on which further information will follow in coming newsletters and online on www.escardio.org.
The Pharmacotherapy in Older People (POP) course will also be held 20-21 October 2022 – onsite in Madrid. It is an engaging and interactive course to improve the professional knowledge and skills on cardiovascular pharmacotherapy in older patients. This is a great opportunity to improve the knowledge pharmacotherapy in older people for general physicians, care of the elderly professionals, nurses, cardiologists, nephrologists, diabetologists, trainees and healthcare professionals dealing with elderly patients in their daily clinical practice.
The All About Clinical Trials (AACT) course will be run 8–9 December 2022 on site in Stockholm, in collaboration with the Karolinska Institutet and the Swedish Cardiac Society. This event will provide a deep insight into the long journey which brings pharmacological compounds from bench to bedside, i.e. from trial design for testing new drugs (generation of evidence and its critical appraisal) to implementation of pharmacological treatments for daily use in science and patient care. This course is essential for clinical cardiologists, clinical pharmacologists and healthcare professionals in general with an interest in translational and clinical research methodologies. Students and trainees will also have an opportunity to acquire or improve knowledge and clinical skills in clinical trial design, management and data interpretation.
We launched a new educational programme: Cardiovascular Pharmacotherapy in Women this year, and the next course will be held in London 24–25 February 2023. The course will address unmet needs and knowledge gaps in the management of cardiovascular disease in women and aims at providing a balanced and practical view on the topic. Particular emphasis will be put on gender specific risk factors, dosing, evidence-based treatments and prevention of disease. The target audience will be health care personnel’s responsible for the care of women with CV conditions, as well as trainees aiming to enter these fields.
Cardiovascular Pharmacotherapists and Trialists of Tomorrow (CPTT) is the Young Community of the ESC Working Group on Cardiovascular Pharmacotherapy, dedicated to young professionals under 40 years old (physicians, nurses, scientists or others) with a special interest in cardiovascular pharmacotherapy and clinical trials. The benefits of joining the CPTT are many and we encourage you to join, it is free of charge. You need to be a member of the WG Cardiovascular Pharmacotherapy, which can be done on this webpage.
On behalf of the Working Group nucleus,
Alexander Niessner, Chairperson 2020–2022 and
Anne Grete Semb, Secretary and Communication Coordinator 2020–2022
Our mission: To reduce the burden of cardiovascular disease.